The U.S. stock market recently experienced a significant rebound, with major indices like the Dow Jones surging over 1,000 points as investors reacted to a flurry of earnings reports and ongoing tariff discussions. In such a volatile market landscape, identifying potential in smaller or newer companies can be particularly rewarding. While "penny stocks" may sound outdated, they still represent opportunities within less-established firms that could offer substantial value when backed by strong financials and clear growth prospects.

Top 10 Penny Stocks In The United States

Click here to see the full list of 789 stocks from our US Penny Stocks screener.

We'll examine a selection from our screener results.

Acrivon Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Acrivon Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing oncology medicines tailored to patients with tumors predicted to respond well, using its proteomics-based platform, and has a market cap of $56.75 million.

Operations: Acrivon Therapeutics, Inc. has not reported any revenue segments as it is a clinical stage biopharmaceutical company.

Market Cap: $56.75M

Acrivon Therapeutics, a pre-revenue biopharmaceutical company with a market cap of US$56.75 million, is navigating the volatile landscape typical of penny stocks. Recent executive changes include the appointment of Dr. Mansoor Raza Mirza as Chief Medical Officer, bringing significant expertise in oncology to the team. The company remains debt-free and has sufficient short-term assets to cover liabilities, providing some financial stability despite ongoing losses and high share price volatility. Acrivon's recent FDA Breakthrough Device designation for its ACR-368 OncoSignature assay highlights potential growth avenues amidst competitive challenges in the biotech sector.

• Click to explore a detailed breakdown of our findings in Acrivon Therapeutics' financial health report.
• Review our growth performance report to gain insights into Acrivon Therapeutics' future.

C4 Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutic candidates to degrade disease-causing proteins, with a market cap of $88.74 million.

Operations: C4 Therapeutics generates revenue from its Pharmaceuticals segment, totaling $35.58 million.

Market Cap: $88.74M

C4 Therapeutics, with a market cap of US$88.74 million, exemplifies the volatility and challenges often seen in penny stocks. The company remains unprofitable, with losses totaling US$105.32 million for 2024, although it has sufficient short-term assets to cover liabilities and is debt-free. Recent board changes include Bruce Downey's retirement announcement without any strategic disagreements. Despite a forecasted revenue growth of 58.87% annually, earnings are expected to decline by an average of 6.5% over the next three years, highlighting potential hurdles amid its clinical-stage developments in biopharmaceuticals.

• Navigate through the intricacies of C4 Therapeutics with our comprehensive balance sheet health report here.
• Gain insights into C4 Therapeutics' future direction by reviewing our growth report.

SmartRent

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SmartRent, Inc. is an enterprise real estate technology company offering management software and applications to rental property stakeholders globally, with a market cap of approximately $152.55 million.

Operations: SmartRent's revenue is primarily derived from its Electronic Security Devices segment, which generated $174.89 million.

Market Cap: $152.55M

SmartRent, with a market cap of US$152.55 million, faces the typical volatility associated with penny stocks but offers some financial stability through its cash runway exceeding three years and no debt. Recent executive changes saw John Dorman appointed interim CEO following the departure of Michael Shane Paladin. Despite revenue declining to US$174.89 million in 2024 from the previous year, SmartRent's strategic innovations like Teams and Smart Launch aim to enhance operational efficiency in property management. However, persistent unprofitability and high share price volatility remain concerns for investors considering this stock category.

• Click here to discover the nuances of SmartRent with our detailed analytical financial health report.
• Examine SmartRent's earnings growth report to understand how analysts expect it to perform.

Next Steps

• Investigate our full lineup of 789 US Penny Stocks right here.
• Seeking Other Investments? Explore 21 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:ACRV NasdaqGS:CCCC and NYSE:SMRT.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com